Skip to main
NEO
NEO logo

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 22%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics Inc has demonstrated a solid financial performance with an adjusted gross margin of 46.8%, reflecting a year-over-year increase of 150 basis points, alongside an adjusted EBITDA margin of 4.2%, which rose 200 basis points and exceeded consensus expectations. The company also reported a revenue per test growth of 2.7%, increasing from $447 to $459 in the fourth quarter of 2024, influenced by pricing strategies, revenue cycle management, and the mix of next-generation sequencing (NGS) tests. Furthermore, NGS testing experienced significant growth of 18% in the first quarter of 2025, indicating a positive trend in demand for advanced oncological diagnostic services.

Bears say

NeoGenomics Inc. is facing significant challenges, as evidenced by its recent non-clinical revenue performance, which totaled $18.3 million, falling short of the $20.9 million consensus estimate and reflecting a decline of 15.6% from prior growth. This decrease, contrasting sharply with the previous 4.4% growth in 4Q24, indicates a troubling slowdown in overall revenue growth, compounded by underlying macroeconomic issues. Furthermore, the company is exposed to risks such as potential setbacks in reimbursement processes, increased competition, and the financial impact of necessary reinvestments, all of which could further erode EBITDA margins and market positioning.

NeoGenomics (NEO) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 22% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 9 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.